Loading
NASDAQFinancial ServicesFinancial - Credit Services
Latest quote
$25.12
+$0.0099 · +0.04%
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Latest quote
$25.12
+$0.0099 · +0.04%
Regular session · ET · Market data may be delayed.
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Day range
Current $25.12
52-week range
Current $25.12
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
52
Mixed
Risk
15
Low Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
Day range
Current $25.12
52-week range
Current $25.12
| Metric (USD) | FY2025 |
|---|---|
| Revenue | 41.46M USD |
| Research and development | 1.55M USD |
| Selling, general, and administrative | 14.76M USD |
| Operating expenses | 16.31M USD |
| Interest expense | 4.8M USD |
| Depreciation and amortization | 40K USD |
| Operating income | 20.28M USD |
| Net income | −2.53M USD |
Company facts updated Oct 15, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
